« Back
Home /
Etomoxir

Etomoxir

Item no.	HY-50202-10mg
Manufacturer	MedChem Express
CASRN	124083-20-1
Amount	10 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 50 mg 5 mg
Category	Oncology Neuroscience Targets for Rodent Neurosciences Cardiovascular Research Myocardial Infarction Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Bladder Cancer Breast Cancer
Type	Inhibitors
Specific against	other
Purity	99.92
Citations	[1]Rupp H, et al. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz. 2002 Nov;27(7):621-36.\|[2]Xu FY, et al. Etomoxir mediates differential metabolic channeling of fatty acid and glycerol precursors into cardiolipin in H9c2 cells. J Lipid Res. 2003 Feb;44(2):415-23.\|[3]Li J, et al. FFA-ROS-P53-mediated mitochondrial apoptosis contributes to reduction of osteoblastogenesis and bone mass in type 2 diabetes mellitus. Sci Rep. 2015 Jul 31;5:12724.\|[4]Luiken JJ, et al. Etomoxir-induced partial carnitine palmitoyltransferase-I (CPT-I) inhibition in vivo does not alter cardiac long-chain fatty acid uptake and oxidation rates. Biochem J. 2009 Apr 15;419(2):447-55.\|[5]O'Connor RS, et al. The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations. Sci Rep. 2018 Apr 19;8(1):6289. Acta Biomater. 2022 Sep 15:150:83-95. Acta Pharm Sin B. 2024 Nov 7. Acta Pharmacol Sin. 2025 May 20. Adv Sci (Weinh). 2024 Nov 26:e2411559. Adv Sci (Weinh). 2025 Nov 6:e07384. Aging Cell. 2024 Aug;23(8):e14184. Ann Med. 2025 Dec;57(1):2497112. Arterioscler Thromb Vasc Biol. 2025 Aug 21. Autophagy. 2025 Jan;21(1):80-101. Biochem Biophys Res Commun. 2017 Feb 5;483(2):860-866. Biochem Biophys Res Commun. 2021 Oct 8:583:135-141. Biochim Biophys Acta Mol Basis Dis. 2024 Jun 25:167314. Biochim Biophys Acta Mol Basis Dis. 2025 May 24:167919. bioRxiv. 2021 Mar 8. bioRxiv. 2023 Apr 17. bioRxiv. 2023 Nov 17. bioRxiv. 2025 April 10. bioRxiv. 2025 May 15. Brain. 2024 Aug 28:awae270. Cancer Cell Int. 2023 May 9;23(1):87. Cancer Cell Int. 2025 May 14;25(1):176. Cancer Cell. 2025 Jun 9;43(6):1108-1124.e11. Cancer Res. 2023 Aug 1;83(15):2461-2470. Cell Biol Int. 2024 Sep;48(9):1378-1391. Cell Death Dis. 2023 Feb 15;14(2):125. Cell Death Dis. 2023 Oct 6;14(10):653. Cell Death Dis. 2025 Apr 14;16(1):291. Cell Death Discov. 2024 May 1;10(1):207. Cell Metab. 2023 Dec 5;35(12):2136-2152.e9. Cell Metab. 2024 May 7;36(5):969-983.e10. Cell Mol Gastroenterol Hepatol. 2025 May 21:101539. Cell Physiol Biochem. 2018;48(6):2318-2336. Cell Prolif. 2021 Nov;54(11):e13134. Cell Rep Med. 2024 May 29:101592. Cell Rep. 2021 Sep 7;36(10):109659. Cell Rep. 2024 Feb 27;43(2):113739. Cell Signal. 2025 Jan 26:111627. Clin Mol Hepatol. 2024 May 10. Clin Transl Med. 2022 Sep;12(9):e1061. Clin Transl Oncol. 2025 Jun;27(6):2557-2567. Commun Biol. 2022 Dec 7;5(1):1340. Engineering. 2024 Sep 6. Eur J Med Res. 2025 Jan 17;30(1):35. FASEB J. 2025 Mar 15;39(5):e70439. Fish Shellfish Immunol. 2024 Aug 12:109829. Food Chem Toxicol. 2022 Nov:169:113450. Free Radic Biol Med. 2022 Sep:190:94-104. Free Radical Bio Med. 2019 Sep:141:372-382. Front Biosci (Landmark Ed). 2024 Feb 6;29(2):66. Front Immunol. 2022 Mar 10;13:771732. Front Oncol. 2021 Apr 22:11:665763. Front Oncol. 2021 Apr 6. Front Pharmacol. 2022 May 16;13:848957. Hepatology. 2022 Dec;76(6):1617-1633. Infect Genet Evol. 2020 Nov;85:104552. Int J Biol Sci. 2021 Oct 11;17(15):4207-4222. Int J Biol Sci. 2022 Mar 14;18(6):2484-2496. Int J Biol Sci. 2025 Jan 1;21(2):725-744. J Agric Food Chem. 2024 Jun 12;72(23):13039-13053. J Biol Chem. 2024 Jul 11:107549. J Biomed Mater Res A. 2022 Aug;110(8):1448-1459. J Cell Biol. 2022 Dec 5;221(12):e202207022. J Cell Sci. 2022 Aug 1;135(15):jcs259090. J Immunother Cancer. 2025 Oct 23;13(10):e012162. J Invest Dermatol. 2023 Oct;143(10):1993-2006.e10. J Orthop Surg Res. 2023 May 26;18(1):386. Johns Hopkins University. 2025 Sep. Med Oncol. 2025 Jul 14;42(8):332. Mol Cell. 2024 Jun 21:S1097-2765(24)00477-5. Mol Med. 2025 Oct 9;31(1):310. Mol Metab. 2024 Jun:84:101953. Nat Commun. 2021 Jun 16;12(1):3660. Nat Commun. 2022 Jun 17;13(1):3486. Nat Commun. 2024 Aug 3;15(1):6587. Nat Commun. 2024 May 7;15(1):3805. Nat Commun. 2025 Feb 1;16(1):1241. Nat Commun. 2025 Jan 2;16(1):212. Nat Commun. 2025 May 15;16(1):4502. Nat Genet. 2025 Mar;57(3):680-693. Nat Metab. 2022 Oct;4(10):1287-1305. Nat Metab. 2025 Sep 30. Neoplasia. 2025 Feb 3:61:101125. Oncogene. 2025 Sep;44(34):3096-3112. Oncol Rep. 2023 Jul;50(1):138. Oncol Rep. 2023 Jul;50(1):141. Oncotarget. 2016 Oct 11;7(41):67071-67086. Pharmacol Res. 2021 Oct:172:105796. PLoS Biol. 2025 Nov 24;23(11):e3003490. Proc Natl Acad Sci U S A. 2021 Nov 16;118(46):e2105950118. Redox Biol. 2018 Oct;19:412-428. Redox Biol. 2021 Oct:46:102082. Research (Wash D C). 2023:6:0087. Research Square Preprint. 2020 Sep. Research Square Preprint. 2022 Feb. Rheumatology (Oxford). 2024 Jun 5:keae320. Sci Adv. 2023 Apr 14;9(15):eadf8522. Sci Adv. 2025 Aug 29;11(35):eadu6271. Sci Immunol. 2023 Sep 29;8(87):eabq2424. Sci Rep. 2024 Jan 18;14(1):1600. Sci Rep. 2025 Aug 20;15(1):30552. SSRN. 6 Dec 2022. Stem Cell Res Ther. 2024 Sep 27;15(1):328. Theranostics. 2020 May 16;10(14):6483-6499. Universidade de São Paulo. Ribeirão Preto, 2021. Vet Microbiol. 2024 Jan:288:109932. Am J Physiol Cell Physiol. 2025 Mar 1;328(3):C776-C790. Am J Physiol Gastrointest Liver Physiol. 2025 Jun 1;328(6):G663-G676. Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e01659-17. Cancer Lett. 2024 Jun 18:217068. Cell Death Dis. 2022 Mar 11;13(3):229. Cell Metab. 2022 Nov 1;34(11):1843-1859.e11. Cell Rep. 2019 Apr 2;27(1):226-237.e4. Cell Stem Cell. 2025 Dec 4;32(12):1849-1868.e15. Dev Cell. 2025 Apr 18:S1534-5807(25)00206-0. J Invest Dermatol. 2023 Oct;143(10):1993-2006.e10. Life Sci. 2024 Aug 1:350:122763. Lipids Health Dis. 2024 Feb 3;23(1):37. Mol Cell. 2020 Oct 1;80(1):43-58.e7. Mol Cell. 2022 Aug 18;82(16):3030-3044.e8. Redox Biol. 2018 Jul;17:180-191. Research Square Preprint. 2023 Aug 1.
Smiles	O=C(OCC)[C@@]1(OC1)CCCCCCOC2=CC=C(C=C2)Cl
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	(R)-(+)-Etomoxir
Shipping Condition	Cool pack
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Metabolism-sugar/lipid metabolism
Manufacturer - Category	Reference compound / Active compounds
Manufacturer - Targets	Apoptosis
Manufacturer - HS Code	H302, H315, H319, H335
Shipping Temperature	Blue Ice
Storage Conditions	-20°C (Powder, protect from light, stored under nitrogen)
Molecular Weight	326.82
Product Description	Etomoxir ((R)-(+)-Etomoxir) is an irreversible inhibitor of carnitine palmitoyltransferase 1a (CPT-1a), inhibits fatty acid oxidation (FAO) through CPT-1a and inhibits palmitate β-oxidation in human, rat and guinea pig.
Manufacturer - Research Area	Cancer; Metabolic Disease
Solubility	DMSO : 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Apoptosis
Clinical information	No Development Reported
UNSPSC Code	12352005
Precautionary	H302, H315, H319, H335

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.